৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Primary Biliary Cholangitis (PBC):
In adults with inadequate response to ursodeoxycholic acid (UDCA) for at least 1 year.
As monotherapy in adults unable to tolerate UDCA.
May be taken with or without food.
If using bile-acid binding resins, separate obeticholic acid dose by at least 4 hours.
Starting dose: 5 mg once daily (adjust according to response and tolerance).
Complete biliary obstruction.
Farnesoid X receptor (FXR) agonist.
FXR is a nuclear receptor in liver, intestine, kidney, and adipose tissue.
Regulates bile acid synthesis, transport, lipid metabolism, and glucose homeostasis.
FXR activation:
Suppresses new bile acid synthesis in hepatocytes.
Increases bile acid transport out of hepatocytes.
Reduces hepatocyte exposure to bile acids.
Hepatic decompensation/failure (sometimes fatal) reported in patients with cirrhosis (Child-Pugh B or C) when dosed more frequently than recommended.
Monitor liver enzymes and signs of decompensation (e.g., worsening renal function, dehydration).
Dose-response relationship observed for liver-related adverse reactions (jaundice, ascites, PBC flare at >10 mg/day).
Lactation: Unknown if excreted in breast milk. Consider benefits of breastfeeding vs. maternal need and potential risks.
>10%:
Pruritus (56–70%)
Fatigue (19–25%)
Severe pruritus (19–23%)
Reduced HDL-C (9–20%)
Abdominal pain/discomfort (10–19%)
1–10%:
Rash (7–10%)
Oropharyngeal pain (7–8%)
Dizziness (7%)
Constipation (7%)
Peripheral edema (3–7%)
Palpitations (3–7%)
Pyrexia (7%)
Thyroid abnormality (4–6%)
Eczema (3–6%)
Bile-acid binding resins: Reduce absorption and efficacy.
Warfarin: May decrease INR → monitor and adjust dose.
CYP1A2 substrates (e.g., theophylline, tizanidine): Exposure may increase → monitor closely.
BSEP inhibitors (e.g., cyclosporine): Avoid use; may worsen bile salt accumulation






Primary Biliary Cholangitis\r\nIndicated for primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA for at least 1 yr or as monotherapy in adults unable to tolerate UDCA
May take with or without food\r\n\r\nConcomitant bile-acid binding resin: Separate obeticholic acid dose by at least 4 hr
$4e
Complete biliary obstruction
Farnesoid X receptor (FXR) agonist\r\n\r\nFXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue that regulates a wide variety of target genes critically involved in the control of bile acid synthesis and transport, lipid metabolism, and glucose homeostasis\r\n\r\nFXR activation suppresses de novo synthesis of bile acids in hepatocytes as well as increasing transport of bile acids out of hepatocytes, thereby reducing exposure of the hepatocytes to bile acid
Hepatic decompensation and failure, in some cases fatal, reported in patients with PBC who have decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when obeticholic acid was dosed more frequently than the recommended starting dosage of 5 mg once weekly\r\n\r\nMonitor patients for elevations in liver enzymes and risks for hepatic decompensation (eg, worsening renal function, dehydration)\r\n\r\nDose response relationship observed in clinical trials for liver-related adverse reactions, including jaundice, worsening ascites, and primary biliary cholangitis flare (doses >10 mg/day)\r\n\r\nLactation\r\nUnknown if distributed in human breast milk\r\n\r\nConsider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition\r\n
>10%\r\nPruritus (56-70%)\r\nFatigue (19-25%)\r\nSevere pruritus (19-23%)\r\nReduced HDL-C (9-20%)\r\nAbdominal pain and discomfort (10-19%)\r\n\r\n1-10%\r\nRash (7-10%)\r\nOropharyngeal pain (7-8%)\r\nDizziness (7%)\r\nConstipation (7%)\r\nPeripheral edema (3-7%)\r\nPalpitations (3-7%)\r\nPyrexia (7%)\r\nThyroid function abnormality (4-6%)\r\nEczema (3-6%)\r\n\r\n
Bile-acid binding resins may reduce the absorption, systemic exposure, and efficacy of obeticholic acid\r\nCoadministration of warfarin and obeticholic acid has been shown to decrease the INR; monitor the INR and adjust warfarin dose accordingly\r\nCoadministration with CYP1A2 substrates (eg, theophylline, tizanidine) may increase exposure of CYP1A2 substrates; monitor CYP1A2 substrates with narrow therapeutic index\r\nAvoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) (eg, cyclosporine); BSEP inhibitors may exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms
N/A





